| Literature DB >> 23771044 |
Caroline B F Mourão1, Elisabeth F Schwartz.
Abstract
The Kunitz-type protease inhibitors are the best-characterized family of serine protease inhibitors, probably due to their abundance in several organisms. These inhibitors consist of a chain of ~60 amino acid residues stabilized by three disulfide bridges, and was first observed in the bovine pancreatic trypsin inhibitor (BPTI)-like protease inhibitors, which strongly inhibit trypsin and chymotrypsin. In this review we present the protease inhibitors (PIs) described to date from marine venomous animals, such as from sea anemone extracts and Conus venom, as well as their counterparts in terrestrial venomous animals, such as snakes, scorpions, spiders, Anurans, and Hymenopterans. More emphasis was given to the Kunitz-type inhibitors, once they are found in all these organisms. Their biological sources, specificity against different proteases, and other molecular blanks (being also K+ channel blockers) are presented, followed by their molecular diversity. Whereas sea anemone, snakes and other venomous animals present mainly Kunitz-type inhibitors, PIs from Anurans present the major variety in structure length and number of Cys residues, with at least six distinguishable classes. A representative alignment of PIs from these venomous animals shows that, despite eventual differences in Cys assignment, the key-residues for the protease inhibitory activity in all of them occupy similar positions in primary sequence. The key-residues for the K+ channel blocking activity was also compared.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23771044 PMCID: PMC3721222 DOI: 10.3390/md11062069
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Protease inhibitors from venomous animals. Some protease inhibitors with less information about sequence or biological activity, as well as some putative protease inhibitors only found by means of transcriptomic approach but not tested against proteases, were not included in this table (some of them are found within the text, with the respective UniProtKB code). Organisms from which the PIs were obtained are indicated by the symbols at left: # sea anemones; + snakes; § scorpions; ¥ spiders; ¤ Anurans; ø Hymenopterans. Capital letters denote the proteases inhibited: T, trypsin; C, chymotrypsin; CL, cathepsin L; CB, cathepsin B; P, papain; K, kallikrein; PK, plasma kallikrein; TK, tissue kallikrein; Pl, plasmin; E, elastase; nE, neutrophil elastase; pE, pancreatic elastase; X, factor Xa; XII, α-factor XIIa; SA, subtilisin A; ptK, proteinase K; Th, thrombin. Structural classes are indicated by symbols: ♦ Kunitz-type motif protease inhibitors; ▯ Kazal-type protease inhibitors; ● thyroglobulin type-1domain; ◊ Ascaris-type motif; ○ Bowman-Birk-type motif.
| Specie | Toxin | UniProt KB | AA a | Protease inhibited | Inhibitory activity b–g | References |
|---|---|---|---|---|---|---|
| # | ♦ AEPI-I | - | 59 III | - | - | [ |
| ♦ AEPI-II | - | 59 III | - | - | [ | |
| ● Equistatin | P81439 | 199 III | Cathepsin L *, | 0.051 (CL), | [ | |
| papain, | 0.57 (P), | |||||
| cathepsin B | 1.4 (CB) b | |||||
| ♦ AEAPI | - | 57 III | Trypsin *, plasmin | 700 IU/mg (T) c | [ | |
| # | ■ Elastase inhibitor | P16895 | 48 III | Porcine elastase | 1.0 d | [ |
| ♦ Kalicludin-1 or AsKC1 | Q9TWG0 | 58 III | Trypsin | <30 d | [ | |
| ♦ Kalicludin-2 or AsKC2 | Q9TWF9 | 58 III | Trypsin | <30 d | [ | |
| ♦ Kalicludin-3 or AsKC3 | Q9TWF8 | 59 III | Trypsin | <30 d | [ | |
| ♦ SA5 II | P10280 | 62 III | Kallikrein, Trypsin | 0.3 (T) d | [ | |
| # | ♦ AXPI-I or AXAPI | P81547 | 58 III | Trypsin *, chymotrypsin, elastase, thermolysin | 1900 IU/mg (T) c | [ |
| ♦ AXPI-II | P81548 | 58 III | Trypsin *, chymotrypsin | 490 IU/mg (T) c | [ | |
| #
| ♦ APEKTx1 | P86862 | 65 III | Trypsin | 124 d | [ |
| #
| ♦ AFAPI-I | - | 56 III | Trypsin *, plasmin | 950 IU/mg (T) d | [ |
| ♦ AFAPI-III | - | 56 III | Trypsin *, plasmin | 900 IU/mg (T) d | [ | |
| # | ♦ Jn-IV | P16344 | 56 III | Trypsin | 9.6 d | [ |
| ♦ InhVJ | - | 56 III | Trypsin *, | 2.49 (T), | [ | |
| chymotrypsin | 21.7 (C) d | |||||
| ♦ APHC1 | B2G331 | 56 III | Trypsin, | 1000 (T), | [ | |
| chymotrypsin | ~5000 (C) d | |||||
| #
| ♦ Inhibitor 4 | - | 48 II | Trypsin, kallikrein *, chymotrypsin | 0.95 (T), 0.49 (K), 33 (C) d | [ |
| #
| ♦ SHTX-3 | B1B5I8 | 62 III | Trypsin | 203 IU/mg c | [ |
| #
| ♦ ShPI-1 | P31713 | 55III | Serine *, | 0.11 (T), | [ |
| cysteine, | 2.3 (C), | |||||
| aspartic proteases | 2.7 (Pl) d | |||||
| ♦ ShPI-2 | P81129 | 55 III | Serine, cysteine, aspartic proteases | n.f. | [ | |
| + | ♦ Dendrotoxin E | P00984 | 59 III | Trypsin *, | 1.0 (T), | [ |
| chymotrypsin | 100 (C) d | |||||
| + | ♦ BBPTI-1 | - | 60 III | Chymotrypsin | 4.77 b | [ |
| ♦ CBPTI-1 | A8Y7N4 | 66 III | Trypsin | 407 b | [ | |
| ♦ CBPTI-2 | A8Y7N5 | 60 III | Trypsin | 666 b | [ | |
| ♦ CBPTI-3 | A8Y7N6 | 60 III | Chymotrypsin | 2.55 b | [ | |
| +
| ♦ HHV inhibitor II | P00985 | 57 III | Trypsin, | - | [ |
| +
| ♦ NNV inhibitor II | P00986 | 57 III | Trypsin | - | [ |
| +
| ♦ Trypsin inhibitor I | P00991 | 61 III | Trypsin *, | 0.34 (T), | [ |
| ♦ Trypsin inhibitor II | - | 62 III | Trypsin *, | 0.56 (T), | [ | |
| ♦ Chymotrypsin inhibitor | P00992 | 65 III | Chymotrypsin *, trypsin, plasma kallikrein | 4.3 (C), 5100 (T) b | [ | |
| +
| ♦ BF9 | P25660 | 65 III | Chymotrypsin | 58 d | [ |
| ♦ Bungaruskunin | B2KTG1 | 59 III | Chymotrypsin *, | 6100 (C) b | [ | |
| +
| ♦ Trypsin inhibitor | P20229 | 57 III | Trypsin | 0.0035 b | [ |
| +
| ♦ NACI | Q5ZPJ7 | 57 III | Chymotrypsin | 25 b | [ |
| +
| ♦ Oh11-1 | P82966 | 58 III | Chymotrypsin | 3520 b | [ |
| ♦ OH-TCI | B6RLX2 | 58 III | Chymotrypsin *, | 84.6 (C), | [ | |
| trypsin | 391 (T) b | |||||
| +
| ♦ PILP-1 | B4ESA2 | 58 III | Trypsin | 55.62 b | [ |
| +
| ♦ TSPI | B7S4N9 | 62 III | Kallikrein *, trypsin, plasmin, elastase, factor Xa, α-factor XIIa | 0.057 (PK), | [ |
| +
| ♦ Textilinin-1 | Q90WA1 | 59 III | Plasmin *, | 0.49 ± 0.02 (Pl), | [ |
| trypsin | 0.76 ± 0.02 (T) b | |||||
| ♦ Textilinin-2 | Q90WA0 | 59 III | Plasmin | 2.2 b | [ | |
| +
| ♦ PIVL | I2G9B4 | 67 III | Trypsin | - | [ |
| +
| ♦ | E7FL11 | 59 III | Metalloprotease 2 | 60 b | [ |
| ♦ | E7FL12 | 59 III | Trypsin *, | 5 (T), | [ | |
| chymotrypsin, | 40 (C), | |||||
| plasmin | 40 (Pl) b | |||||
| ♦ | E7FL13 | 59 III | Trypsin, | 5 (T), | [ | |
| plasmin | 100 (Pl) b | |||||
| § | ♦ Fraction IX-1-a | - | - | Trypsin *, | 19.2 IU/mg (T), | [ |
| kallikrein | 87 IU/mg (K) c | |||||
| § | ♦ rHg1 | P0C8W3 | 67 III | Trypsin | 107 d | [ |
| § | ♦ rLmKTT-1a | P0DJ46 | 59 III | Trypsin | 140 d | [ |
| ♦ rLmKTT-1b or SdPI | P0DJ45 | 59 III | Trypsin | 160 d | [ | |
| ♦ rLmKTT-1c | P0DJ48 | 59 III | Trypsin | 124 d | [ | |
| § | ♦ rBmKTT-1 | P0DJ49 | 59 III | Trypsin | 136 d | [ |
| ♦ rBmKTT-2 | P0DJ50 | 58 IV | Trypsin | 420 d | [ | |
| ♦ rBmKTT-3 | P0DJ47 | 70 III | Trypsin | 760 d | [ | |
| § | ◊ rSjAPI | - | 64 V | Chymotrypsin *, | 97.1 (C), | [ |
| elastase | 3700 (E) b | |||||
| ¥ | ♦ HWTX-XI | P68425 | 55 III | Trypsin | 0.23 d | [ |
| ¥ | ♦ AvKTI | K7YYJ2 | 57 III | Trypsin, | 7.34 (T), | [ |
| chymotrypsin, | 37.75 (C), | |||||
| plasmin *, | 4.89 (Pl), | |||||
| neutrophil elastase | 169.07 (E) b | |||||
| ♦ AvCI | L7X735 | 70 IV | Chymotrypsin, | 49.85 (C), | [ | |
| subtilisin A, | 20.51 (SA), | |||||
| proteinase K, | 65.42 (ptK), | |||||
| neutrophil elastase, | 8.74 (nE), | |||||
| pancreatic elastase | 11.32 (pE) b | |||||
| ¤ | ◊ BSTI | Q90248 | 60 V | Trypsin, | 80–100 (T), | [ |
| thrombin | 1300 (Th) b | |||||
| ¤ | ◊ BMTI | Q8QFP3 | 60 V | Trypsin | 60 b | [ |
| ¤ | ◊ Trypsin inhibitor | - | 61 V | Trypsin | ~20,000 e | [ |
| ¤ | ◊ BOTI | Q800F0 | 60 V | - | - | [ |
| ¤ | ◊ BVTI | Q800E9 | 60 V | - | - | [ |
| ¤ | ◊ BMSI 1 | B1P2F8 | 60 V | Trypsin, thrombin | 20 (T), 150 (Th) b | [ |
| ◊ BMSI 2 | B1P2F9 | 60 V | - | - | [ | |
| ¤ | Hylaserpin S1 | H6SWK9 | 392 | Trypsin, | 55 (T), | [ |
| chymotrypsin | 310 (C) b | |||||
| ◊ Hylaserpin S2 | H6SWL0 | 56 V | Trypsin | 72 b | [ | |
| ¤ | BATI | - | - | Trypsin | 14 b | [ |
| Trypsin | 4.6 × 106 (T), | |||||
| Baserpin | - | - | chymotrypsin, | 8.9 × 106 (C), | [ | |
| elastase | 6.8 × 106 (E) f | |||||
| ¤ | KPHTI | - | - | Trypsin | 27 c | [ |
| ¤ | ■ PSKP-1 | P83578 | 58 III | Prolyl endopeptidase | 124 ± 56 g | [ |
| ■ PSKP-2 | P83579 | 58 III | - | - | [ | |
| ¤ | PI01 | K9N0E2 | 78 III | - | - | [ |
| PI02 | K9N1K5 | 77 III | - | - | [ | |
| PI03 | K9N2T9 | 53 III | - | - | [ | |
| ¤ | ■ ACKTI | I7J523 | 52 III | Trypsin | 1.9 b | [ |
| ¤ | ♦ Kunitz-type PI | J9UVV9 | 57 III | Trypsin | - | [ |
| ¤ | ♦ KSCI | F8K9Q3 | 62 III | Chymotrypsin | - | [ |
| ¤ | ♦ Anntoxin | C7AR58 | 60 II | Trypsin | 25 b | [ |
| ¤ | OGTI | - | 17 II | Trypsin | 400 b | [ |
| ¤ | HV-BBI | B1VC43 | 18 I | Trypsin | 18.8 + 1.8 b | [ |
| ø | ♦ Bicolin | C0LNR2 | 54 III | Trypsin *, thrombin | 550 (T), 26,000 (Th) b | [ |
| ø | ♦ Bi-KTI | G3LH89 | 58 III | Plasmin | 43.53 g, 3.6 b | [ |
| ø | ♦ Bt-KTI | D8KY58 | 58 III | Plasmin | 2.01 b | [ |
* Protease against which the inhibitor showed more potent activity; a Number of amino acid residues and disulfide bridges (superscript) of the mature peptide; b Measured in terms of Ki value (nM); c Measured in terms of inhibitory units (IU)/mg, where 1 IU is the amount of protein that inhibit one unit of enzyme; d Measured in terms of Kd value (nM); e Unique concentration used (nM); f Association rate (kass) measured in M−1·s−1; g Measured in terms of IC50 value (nM); n.f. means inhibitory activity not found by the authors; - Means data not available in the literature.
Potassium channel blocking activity of Kunitz-type motif protease inhibitor peptides from animal venoms. Scorpion and spider mutated peptides were not considered.
| Source | Peptide | IC50 (nM) | Target | Ref. |
|---|---|---|---|---|
| Sea anemone | APEKTx1 * | 0.9 ± 0.1 | Kv1.1 | [ |
| AsKC1 * | 2800 | Kv1.2 | [ | |
| AsKC2 * | 1100 | Kv1.2 | [ | |
| AsKC3 * | 1300 | Kv1.2 | [ | |
| SHTX-3 * | 650 | Synap a | [ | |
| Cone snail | Conk-S1 | 1.33 ± 0.5 |
| [ |
| Snake | α-DTX | 0.4–150 | Kv1.1, Kv1.2, Kv1.6 | [ |
| DTX-I | 0.13–50 | Kv1.1, Kv1.2, Kv1.6 | [ | |
| DTX-K | 0.03 | Kv1.1 | [ | |
| δ-DTX | 0.029–1.8 | Kv1.1 | [ | |
| DaE | 300 | Kv1.1 | [ | |
| Scorpion | Hg1 * | 6.2 ± 1.2 | Kv1.3 | [ |
| LmKTT-1a * | 1580 | Kv1.3 | [ | |
| LmKTT-1b * | >1000 | Kv1.3 | [ | |
| LmKTT-1c * | >1000 | Kv1.3 | [ | |
| BmKTT-1 * | 129.7 ± 31.3 | Kv1.3 | [ | |
| BmKTT-2 * | 371.3 ± 82.1 | Kv1.3 | [ | |
| BmKTT-3 * | >1000 | Kv1.3 | [ | |
| Spider | HWTX-XI * | 2570 | Kv1.1 | [ |
* Peptides that also present protease inhibitory activity, as shown in Table 1; a Activity obtained through synaptosomal binding assay.
Figure 1Representative alignment of toxins with the Kunitz-type motif from venomous animals. Organisms from which the polypeptides were obtained are indicated by the colored lines at left: blue, sea anemones; grey, snakes; red, scorpions; yellow, spider; green, Anurans; purple, Hymenopterans; black, cone snail. The toxins that present potassium channel blocking activity are indicated by symbols after their names: ●, K+ channel blockers with no protease inhibitory activity or still not tested against proteases; ♦ and ◊, dual-function toxins, where ♦ denotes toxins with stronger potency in K+ channels than those indicated by ◊. The other polypeptides, without symbols, are all serine protease inhibitors. The alignment was generated by ClustalW [170] and the consensus sequence was colored using Chroma and manual edition [171]. Key residues for K+ channel blocking activity are highlighted in red. Key residues for protease inhibition with more specificity to trypsin or chymotrypsin are highlighted in magenta and cyan, respectively. Some of them were suggested to be key residues by sequence similarity with other toxins. The P1 site residues are pointed by an arrow. Capital letters denote amino acids. Lower-case letters denote: b, big; p, polar; h, hydrophobic; a, aromatic. The known conserved disulfide bridges are labeled in black lines. The black dotted line suggests a possible new disulfide bridge in scorpion venom PIs [99]. The numbers within parenthesis mean amino acid residues from the C-terminus of the peptides that were not completely shown in this alignment.
Figure 2Tridimensional structures of polypeptides from venomous animals with the Kunitz-type inhibitor motif (A–D) and bovine pancreatic trypsin inhibitor (BPTI): trypsin complex (E). (A) ShPI-1 (PDB code 1SHP) from the sea anemone Stoichactis helianthus; (B) conkunitzin-S1 (PDB code 2CA7) from the cone snail Conus striatus; (C) HWTX-XI (PDB code 2JOT) from the spider Ornithoctonus huwena; (D) anntoxin (PDB code 2KCR) from the frog Hyla annectans; (E) BPTI:trypsin complex (PDB code 3OTJ). The structures are shown as ribbon diagrams, where α-helixes are indicated by red color, β-strands by yellow, 310-helix by dark blue; and disordered structure by silver. In detail, Lys residue at P1 position (cyan at A, C and D). In BPTI:trypsin complex, interacting amino acid residues are shown in dark grey for BPTI (Lys15 residue at P1 position) and in orange for trypsin (Asp189 at S1 position). A, C, D and E were obtained with the software VMD (visual molecular dynamics) [185], whereas B was obtained with the software Discovery Studio 3.5 (Accelrys, Inc., San Diego, CA, USA).